Home

John E Bishop

CIK 1308911 · See Remarks · last filed 2026-08-25

John E Bishop is a corporate insider who has filed 136 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider sold $76.2K of ARDX on Aug 25, 2026. Across all open-market trades the lifetime net is −$6.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.12M

Companies

4

Total Filings

136

Lifetime Open-Market Net

-$6.51M

Filer Profile

Reported Address
675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARDX See Remarks 317,095 $3.54 $1.12M -$109.2K 4 2026-08-25
Lyra Therapeutics, Inc. (LYRA) Delisted Chief Technology Officer — $0.70 — $0 2 2024-02-01
Forma Therapeutics Holdings, Inc. (FMTX) Delisted SVP, Chief Technology Officer 0 $20.01 $0 $0 3 2022-10-14
MOMENTA PHARMACEUTICALS INC (MNTA) Delisted Senior VP, Pharmaceutical Scie 157,640 — — -$6.40M 124 2016-05-23

Recent Filings

136 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-25 ARDX Sell (S) −19,750 -$76.2K EDGAR
2026-08-21 ARDX Notice (144) −25,500 -$102.8K EDGAR
2026-05-22 ARDX Sell (S) −2,306 -$14.5K EDGAR
2026-05-19 ARDX Notice (144) −3,700 -$23.1K EDGAR
2026-02-23 ARDX Sell (S) −3,179 -$18.6K EDGAR
2026-02-20 ARDX Notice (144) −3,700 -$21.2K EDGAR
2026-01-26 ARDX Grant (A) +124,330 $0 EDGAR
2024-02-01 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2023-02-28 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2022-10-14 Forma Therapeutics Holdings, Inc. (FMTX) Delisted Mixed −47,950 $0 EDGAR
Showing 1–10 of 136
Page 1 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.